Clinical trials
HER2 Positive clinical trials
Below are recruiting her2 positive clinical trials, each written for real people, not researchers. We’re tracking 346 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06532006RecruitingPhase 3
HLX22 plus trastuzumab and chemo for HER2+ stomach cancer
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Anaheim, CaliforniaAges 18 years+ - NCT06561555RecruitingPhase 2
Testing a new drug for advanced HER2-positive Paget's disease
This trial tests an investigational drug called Disitamab Vedotin for people with advanced Paget's disease that tests positive for HER2. It aims to see if the drug can shrink tumors or improve skin lesions.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06589830RecruitingPhase 2
TL938 with Trastuzumab for HER2+ Colorectal Cancer
This trial is testing a new combination of drugs (TL938 and trastuzumab) for people with a specific type of advanced colorectal cancer that is HER2-positive and RAS wild-type. It may offer a new option if you have already tried standard chemotherapy and a blood vessel-blocking drug.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06641544RecruitingPhase 4
Testing different drug combos for HER2-positive breast cancer
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
Shanwei, GuangdongAges 18–70 - NCT06686394RecruitingPhase 1/Phase 2
New drug combo for HER2+ breast cancer that has spread
This trial tests a new drug, patritumab deruxtecan, combined with other cancer treatments for people with advanced HER2+ breast cancer that cannot be removed by surgery. It may be an option if you have already tried other HER2-targeted therapies.
Aurora, ColoradoAges 18 years+ - NCT04968964Recruiting
Monitoring test for CDK4/6 drugs in metastatic breast cancer
This study follows people with hormone receptor–positive, HER2-negative metastatic breast cancer who are taking CDK4/6 inhibitor treatment (with or without an added blood test called DiviTum®). The goal is to see how well the standard treatment is working and whether DiviTum® (a serum TK1 activity test) can help guide monitoring.
St Louis, MissouriAges 18 years+ - NCT06730373RecruitingPhase 2
RC48, sintilimab, and S-1 for advanced HER2-positive stomach cancer
This trial tests a combination of three drugs—RC48 (a targeted therapy), sintilimab (an immunotherapy), and S-1 (a chemotherapy pill)—as a first treatment for advanced HER2-positive stomach cancer that has not been treated before. The goal is to see if this triple therapy works better than current options.
Zhengzhou, HenanAges 18–75 - NCT06770296RecruitingPhase 1
Finding the best dose of pyrotinib for first-line advanced HER2 breast cancer
This study tests a new way to give pyrotinib, a targeted pill for HER2-positive breast cancer, to people whose cancer has spread or come back and who have not had other treatments for this stage. The goal is to find the best dose to control cancer while managing side effects.
Nanjing, JiangsuAges 18–75 - NCT06892093Recruiting
Probiotics to prevent diarrhea from neratinib in breast cancer
This trial tests whether taking probiotics can help prevent diarrhea caused by the breast cancer drug neratinib. If you are a woman with HER2-positive breast cancer and are about to start neratinib, this study may help manage a common side effect.
Guangzhou, GuangdongAges 18 years+ - NCT06927180RecruitingPhase 2
Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Zhengzhou, HenanAges 18–70 - NCT06928818Recruiting
T-DM1 after T-DXd for advanced HER2-positive breast cancer
This trial looks at whether a different targeted therapy, T-DM1, can work for women with advanced HER2-positive breast cancer after they have already tried another targeted therapy called T-DXd (Enhertu). If you have progressed while on T-DXd and have not had more than three previous treatments for advanced cancer, you may be able to join.
SeoulAges 19 years+ - NCT07003074RecruitingPhase 3
New drug TQB2102 vs standard therapy for HER2+ breast cancer
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hefei, AnhuiAges 18–75 - NCT07007559RecruitingPhase 2
Evorpacept with trastuzumab and chemo for HER2+ breast cancer
This trial tests a new drug called evorpacept combined with trastuzumab (Herceptin) and a chemotherapy drug of your choice. It is for people with HER2-positive breast cancer that has spread and who have already tried the drug Enhertu.
Tucson, ArizonaAges 18 years+ - NCT07008976RecruitingPhase 3
Testing TQB2102 versus standard treatment for HER2-positive advanced breast cancer
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
Bengbu, AnhuiAges 18–75 - NCT07053085RecruitingPhase 2
Surgery or radiation for stable HER2+ breast cancer spread
This study tests whether combining surgery or strong focused radiation with standard treatment can help people whose HER2-positive breast cancer has spread to a few spots (5 or fewer) in the body, but not the brain. It's for patients whose cancer is stable after at least 3 months of first-line therapy.
Basking Ridge, New JerseyAges 18 years+ - NCT07057427RecruitingPhase 3
Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Zhengzhou, HenanAges 18–70 - NCT07095023Recruiting
Oral chemo and targeted therapy before breast cancer surgery
This trial tests a combination of an oral chemotherapy pill (paclitaxel) with two targeted antibodies (pertuzumab and trastuzumab) given before surgery for HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07117864Recruiting
T-DXd with brain radiation for HER2+ breast cancer
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07233499RecruitingPhase 2
Nebivolol for heart protection during breast cancer treatment
This trial tests if the drug nebivolol can protect the heart from damage caused by trastuzumab (Herceptin) in women with HER2-positive breast cancer. If effective, it may help prevent heart problems while still allowing cancer treatment.
CairoAges 18–65 - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT01785420RecruitingPhase 3
Trastuzumab before breast surgery for HER2-positive cancer
This trial tests whether giving trastuzumab before surgery can improve outcomes for people with HER2-positive early breast cancer. Trastuzumab is a targeted medicine that helps treat HER2-driven cancer before the tumor is removed.
MumbaiAges 18–80 - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Gilbert, ArizonaAges 30 years+ - NCT07405476RecruitingPhase 2
Zanidatamab before surgery for HER2 positive colon or rectal cancer
This trial tests if the drug zanidatamab, given before surgery, can help treat colon or rectal cancer that has a specific marker called HER2. The goal is to see if this approach can shrink tumors and improve outcomes for people whose cancer has not spread to other parts of the body.
Atlanta, GeorgiaAges 18 years+
Hear when a new HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive?
- Yes. Clin2 currently lists 346 recruiting her2 positive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.